Shi-Yi Wang, MD, PhD
Senior Research Scientist in EpidemiologyDownloadHi-Res Photo
Cards
Contact Info
About
Titles
Senior Research Scientist in Epidemiology
Biography
Dr. Wang is an Associate Professor at the Yale School of Public Health, faculty member of Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, and faculty member of Public Health Modeling Concentration, Yale School of Public Health. His primary interests focus on outcomes research and decision science. He is interested in combining systematic literature reviews, secondary data analyses, and simulation modeling to examine issues that are critical to clinicians and policy makers’ decision making. He has been working on several breast cancer projects, including an evaluation of preoperative breast MRI, development of an individualized decision aid to help radiotherapy decision-making, and assessment of sentinel lymph node biopsy for patients with ductal carcinoma in situ. He is also evaluating end-of-life care quality. He has served as the primary investigator or co-investigator in several projects (funded by Yale Cancer Center, AHRQ, NCI, ACS, and PCORI).
Appointments
Chronic Disease Epidemiology
Senior Research ScientistPrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Chronic Disease Epidemiology
- Chronic Disease Epidemiology (CDE)
- COPPER Center
- Public Health Modeling
- Yale Cancer Center
- Yale School of Public Health
- Yale School of Public Health - NEW
Education & Training
- PhD
- University of Minnesota (2012)
- MD
- Taipei Medical College (1992)
Research
Overview
Medical Research Interests
Breast Neoplasms; Terminal Care
Public Health Interests
Aging; Cancer; End-of-life Care; Global Health; Health Care Quality, Efficiency; Modeling
ORCID
0000-0002-3294-5784
Research at a Glance
Yale Co-Authors
Frequent collaborators of Shi-Yi Wang's published research.
Publications Timeline
A big-picture view of Shi-Yi Wang's research output by year.
Research Interests
Research topics Shi-Yi Wang is interested in exploring.
Cary Gross, MD
Xiaomei Ma, PhD
Michael S. Leapman, MD, MHS
Natalia Kunst, PhD
Kenneth B. Roberts, MD
Lawrence Saperstein, MD
81Publications
2,853Citations
Breast Neoplasms
Terminal Care
Publications
2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseAsymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study.
Ji M, Shih Y, Huber J, Wang M, Feuer E, Etzioni R, Wang S, Chang S. Asymptomatic Incidence of Monoclonal Gammopathy of Undetermined Significance and Preclinical Duration to Myeloma Diagnosis: A Modeling Study. Cancer Epidemiology Biomarkers & Prevention 2024, of1-of8. PMID: 39106151, DOI: 10.1158/1055-9965.epi-24-0490.Peer-Reviewed Original ResearchAltmetricConceptsNHB populationNHW populationsPreclinical durationNon-HispanicNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyNutrition Examination SurveyPopulation-based screeningMultiple myelomaNHW counterpartsExamination SurveyMGUS prevalenceMonoclonal gammopathyIncidence rateNHWNatural history of MMMM incidenceNHBIncidence of monoclonal gammopathyCumulative riskHistory of MMMGUS to MMPopulation age distributionEpidemiologyAsymptomatic incidenceTreatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma
Fiala M, Ji M, Shih Y, Huber J, Wang M, Johnson K, Gasoyan H, Wang R, Colditz G, Wang S, Chang S. Treatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39209567, DOI: 10.1016/j.clml.2024.07.017.Peer-Reviewed Original ResearchConceptsStem cell transplantationCell transplantationMyeloma therapyMultiple myelomaContinuous enrollmentAssociated with early detectionMulti-State Medicaid DatabaseMultivariate logistic regressionMyeloma patientsSolid tumorsHigh medical needMyeloma treatmentHematological cancersMyelomaPatientsMedicaid databaseClaims-based datasetScreening testAcute medical eventsLogistic regressionEarly detectionDiscontinuous enrollmentMedical needContinuous Medicaid coverageCancer diagnosisPersonalized risk assessment of new onset depression in long-term cancer survivors.
Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.Peer-Reviewed Original ResearchConceptsHistory of depressionIncidence of depressionCumulative incidence of depressionRisk of developing depressionLong-term survivorsPredictors of depressionCancer survivorsDisease specific factorsCumulative incidenceNon-HispanicHigher risk of developing depressionRectal cancerLong-term cancer survivorsBreast cancer survivorsCensus tract povertyColon cancerEpisodes of bipolar I disorderPrevalence of depressionMean survival time modelsDiagnosis of depressionReceipt of treatmentAssociated with prior historyHormone receptor statusPatients aged <Adjuvant endocrine therapyFrom criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity.
Ji M, Wang M, Shih Y, Huber J, Fiala M, Wang R, Sanfilippo K, Thomas T, Wang S, Schoen M, Chang S. From criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity. Journal Of Clinical Oncology 2024, 42: 7556-7556. DOI: 10.1200/jco.2024.42.16_suppl.7556.Peer-Reviewed Original ResearchConceptsInternational Myeloma Working GroupMagnetic resonance imagingFree light chainsMGUS patientsMM casesActive MMDiagnostic criteriaMultiple myelomaPlasma cellsClonal bone marrow plasma cellsComputed tomographyOld criteriaPositron emission tomography-CTBone marrow plasma cellsSerum free light chainsSLiM-CRAB criteriaProgression to MMClonal plasma cellsMarrow plasma cellsMM patient outcomePlasma cell malignancyAggressive diagnostic strategyInternational Classification of Diseases (ICD)-9/10 codesCRAB symptomsPositive detection ratePD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchConceptsMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchPD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.Peer-Reviewed Original ResearchImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
Academic Achievements & Community Involvement
honor The Population Science Research Prize
Other AwardYale Cancer CenterDetails01/31/2017United Stateshonor The Distinguished Student Mentor Award
Other AwardYale School of Public HealthDetails06/30/2016United States
News
News
- August 07, 2023
Screening Mammograms Carry Risks for Older Women, Study Finds
- May 05, 2023
Becca Levy and the Fight Against Ageism
- March 05, 2023
Improving Care of Patients Receiving Advanced Cancer Treatment
- June 25, 2020Source: American Heart Association News
COVID-19 highlights long-term inequities in some communities
Get In Touch
Contacts
Email
Academic Office Number
Locations
60 College Street
Academic Office
Ste 432
New Haven, CT 06510